Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

APELLIS PHARMACEUTICALS, INC.

(APLS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Health Care Stocks Ail During Friday Trading

09/10/2021 | 04:03pm EDT


© MT Newswires 2021
All news about APELLIS PHARMACEUTICALS, INC.
10/18APELLIS PHARMACEUTICALS : and Sobi Receive Positive CHMP Opinion for Aspaveli (pegcetacopl..
AQ
10/15APELLIS PHARMACEUTICALS : Swedish Orphan Biovitrum Say PNH Treatment Candidate Aspaveli Re..
MT
10/15APELLIS PHARMACEUTICALS : and Sobi Receive Positive CHMP Opinion for Aspaveli® (pegcetacop..
AQ
10/15SWEDISH ORPHAN BIOVITRUM : Aspaveli® (pegcetacoplan) receives positive CHMP opinion for tr..
AQ
10/15Analysis-Deals, data buzz could help biotech shares exit Wall St's 'no man's land'
RE
10/15Deals, data buzz could help biotech shares exit Wall St's 'no man's land'
RE
10/06APELLIS PHARMACEUTICALS : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
10/05APELLIS PHARMACEUTICALS : Wedbush Adjusts Price Target for Apellis Pharmaceuticals to $31 ..
MT
09/30APELLIS PHARMACEUTICALS : Releases Detailed Pegcetacoplan Trial Data, Plans to File for FD..
MT
09/30EFFICACY OF INTRAVITREAL PEGCETACOPL : results from the DERBY and OAKS trials
PU
More news
Analyst Recommendations on APELLIS PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 24,7 M - -
Net income 2021 -672 M - -
Net cash 2021 256 M - -
P/E ratio 2021 -4,08x
Yield 2021 -
Capitalization 2 887 M 2 887 M -
EV / Sales 2021 107x
EV / Sales 2022 21,3x
Nbr of Employees 445
Free-Float 79,9%
Chart APELLIS PHARMACEUTICALS, INC.
Duration : Period :
Apellis Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APELLIS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 33,18 $
Average target price 67,50 $
Spread / Average Target 103%
EPS Revisions
Managers and Directors
Cedric Francois President, Chief Executive Officer & Director
Timothy Eugene Sullivan Chief Financial Officer & Treasurer
Lok Chung Chan Chairman
Pascal Deschatelets Chief Scientific Officer
Federico Grossi Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
APELLIS PHARMACEUTICALS, INC.-41.31%2 921
CSL LIMITED4.59%99 388
WUXI BIOLOGICS (CAYMAN) INC.14.69%62 669
SAMSUNG BIOLOGICS CO.,LTD.5.08%47 893
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.10.16%40 199